Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gabapentin/trazodone hydrochloride - Angelini

Next Previous
Drug Profile

Gabapentin/trazodone hydrochloride - Angelini

Alternative Names: Gabapentin/trazodone - Angelini; Trazodone hydrochloride/gabapentin FDC - Angelini; Trazodone/gabapentin FDC - Angelini

Latest Information Update: 24 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angelini Group
  • Class Amines; Aminobutyric acids; Antidepressants; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Erectile dysfunction therapies; Gabapentinoids; Non-opioid analgesics; Piperazines; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Alpha adrenergic receptor agonists; CACNA2D1 protein modulators; GABA receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic neuropathies

Most Recent Events

  • 24 Mar 2021 Phase-II development is ongoing Czech Republic, United Kingdom and Poland (PO) (EudraCT2018-000133-12)
  • 06 Jun 2020 Angelini Group completes phase-II clinical trials in Diabetic neuropathies in Czech Republic, United Kingdom and Poland (PO) (EudraCT2018-000133-12)
  • 20 Nov 2018 Phase-II clinical trials in Diabetic neuropathies in Czech Republic, United Kingdom (PO) (NCT03749642)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top